Literature DB >> 23315297

Key elements in adverse drug interaction safety signals: an assessment of individual case safety reports.

Johanna Strandell1, G Niklas Norén, Staffan Hägg.   

Abstract

BACKGROUND: A large proportion of potential drug interactions are known from pre-authorization studies, but adverse drug reactions (ADRs) due to interactions (adverse drug interactions) are often first detected through astute observation in clinical practice. Individual case safety reports (ICSRs) are collected from broad patient populations and allow for the identification of groups of similar reports. Systematic screening for adverse drug interactions in ICSRs will require an understanding of which information on these reports can be suggestive of adverse drug interactions.
OBJECTIVE: The aim of the study was to identify what reported information may support the identification of drug interaction safety signals in collections of ICSRs.
METHODS: Three previously published safety signals of suspected adverse drug interactions were re-evaluated. To this end, 137 reports related to these signals were retrieved from the WHO Global ICSR Database, VigiBase™, and corresponding original reports were obtained from national pharmacovigilance centres. Criteria from an operational score for causality analysis of drug interactions of clinical cases, the Drug Interaction Probability Scale (DIPS), were applied to each of these reports with the aim of identifying what supportive information tends to be available in ICSRs. For three DIPS elements (plausible time course, resolution of the ADR after terminating the drug inducing the interaction without changes in affected drug therapy (positive dechallenge) and alternative causes of the reaction) we also compared the amount of information in VigiBase™ and in original reports, and in free text and structured data.
RESULTS: Commonly fulfilled DIPS elements on reports supporting an adverse drug interaction signal were plausible time course (50 reports; 36%) and positive dechallenge (8 reports; 6%). Alternative causes for the observed adverse reaction were observed in 72 (53%) reports. We found limited differences between VigiBase™ and original reports for the structured data, although a substantial amount of additional information was available in free text in original reports.
CONCLUSIONS: Information on plausible time courses and resolution of the adverse reaction upon withdrawal of the drug suspected to have induced the interaction may be a useful element in identifying suspected adverse drug interactions from ICSRs. Of these, plausible time course is by far the most commonly reported element in the three signals studied here. Our analysis also demonstrated the importance of sharing and analysing information available in free text where relevant clinical details are often available, such as those mentioned above, along with severity and dosage changes.

Entities:  

Mesh:

Year:  2013        PMID: 23315297     DOI: 10.1007/s40264-012-0003-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  13 in total

1.  Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres.

Authors:  P Pouyanne; F Haramburu; J L Imbs; B Bégaud
Journal:  BMJ       Date:  2000-04-15

2.  Adverse drug reactions as a cause for admissions to a department of internal medicine.

Authors:  Tom Mjörndal; Marit Danell Boman; Staffan Hägg; Martin Bäckström; Bengt-Erik Wiholm; Anders Wahlin; Rune Dahlqvist
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Jan-Feb       Impact factor: 2.890

3.  Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.

Authors:  Roberto Leone; Lara Magro; Ugo Moretti; Paola Cutroneo; Martina Moschini; Domenico Motola; Marco Tuccori; Anita Conforti
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

4.  Proposal for a new tool to evaluate drug interaction cases.

Authors:  John R Horn; Philip D Hansten; Lingtak-Neander Chan
Journal:  Ann Pharmacother       Date:  2007-03-27       Impact factor: 3.154

5.  Drug-drug interactions - a preventable patient safety issue?

Authors:  Johanna Strandell; Andrew Bate; Marie Lindquist; I Ralph Edwards
Journal:  Br J Clin Pharmacol       Date:  2007-07-17       Impact factor: 4.335

6.  Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.

Authors:  Johanna Strandell; Ola Caster; Andrew Bate; Niklas Norén; I Ralph Edwards
Journal:  Drug Saf       Date:  2011-03-01       Impact factor: 5.606

7.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

8.  Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study.

Authors:  Sebastian Schneeweiss; Joerg Hasford; Martin Göttler; Annemarie Hoffmann; Ann-Kathrin Riethling; Jerry Avorn
Journal:  Eur J Clin Pharmacol       Date:  2002-06-12       Impact factor: 2.953

9.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Authors:  Munir Pirmohamed; Sally James; Shaun Meakin; Chris Green; Andrew K Scott; Thomas J Walley; Keith Farrar; B Kevin Park; Alasdair M Breckenridge
Journal:  BMJ       Date:  2004-07-03

10.  Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.

Authors:  Antoine Pariente; Fleur Gregoire; Annie Fourrier-Reglat; Françoise Haramburu; Nicholas Moore
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more
  5 in total

1.  Characteristics of drugs safety signals that predict safety related product information update.

Authors:  Widya N Insani; Alexandra C Pacurariu; Aukje K Mantel-Teeuwisse; Liana Gross-Martirosyan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-05-24       Impact factor: 2.890

2.  A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.

Authors:  Sara Hult; Daniele Sartori; Tomas Bergvall; Sara Hedfors Vidlin; Birgitta Grundmark; Johan Ellenius; G Niklas Norén
Journal:  Drug Saf       Date:  2020-08       Impact factor: 5.606

3.  Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.

Authors:  Silvia Fernandez; Camille Lenoir; Caroline Samer; Victoria Rollason
Journal:  Pharmacol Res Perspect       Date:  2020-10

4.  Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis.

Authors:  Chiara Giofrè; Francesca Scicchitano; Caterina Palleria; Carmela Mazzitello; Miriam Ciriaco; Luca Gallelli; Laura Paletta; Giuseppina Marrazzo; Christian Leporini; Pasquale Ventrice; Claudia Carbone; Francesca Saullo; Pierandrea Rende; Michele Menniti; Laura Mumoli; Serafina Chimirri; Marinella Patanè; Stefania Esposito; Felisa Cilurzo; Orietta Staltari; Emilio Russo; Giovambattista De Sarro
Journal:  J Pharmacol Pharmacother       Date:  2013-12

Review 5.  Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase.

Authors:  Silvia Fernandez; Camille Lenoir; Caroline Flora Samer; Victoria Rollason
Journal:  J Pers Med       Date:  2021-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.